Axsome Therapeutics Inc
AXSM - Insider Information
Get informed when a big investor buys or sells
+ FollowMarket Cap$7.57B
Close$
$23.38
82.9% downside
Current Fair Value
82.9% downsideOvervalued by 82.9% based on the discounted cash flow analysis.
Insider Trades
Loading insider trades…
Congress Trades
Loading congress trades…
Share Statistics
| Market cap | $7.57 Billion |
|---|---|
| Enterprise Value | $7.46 Billion |
| Earnings per Share | $-3.68 |
| Beta | 0.6 |
| Outstanding Shares | 51,500,690 |
Return
| Return on Equity | -230.05% |
|---|---|
| Return on Assets | -25.17% |
| Return on Invested Capital | -57.44% |
Valuation & Multiples
| P/E Ratio | -38.51 |
|---|---|
| PEG | -553.03 |
| Price to Sales | 9.13 |
| Price to Book Ratio | 137.0 |
| Enterprise Value to Revenue | 9.61 |
| Enterprise Value to EBIT | -43.18 |
| Enterprise Value to Net Income | -39 |
| Total Debt to Enterprise | 0.03 |
| Debt to Equity | 2.63 |
Revenue Sources
No data
Last Earnings Call
Report Date
November 2, 2026
EPS Estimate
$-0.63
Consensus analyst estimateRevenue Estimate
$249.19 M
Consensus analyst estimateNext Earnings Call
Expected Date
February 22, 2027
EPS Estimate
$-0.07
Consensus analyst estimateRevenue Estimate
$282.43 M
Consensus analyst estimateInstitutional Put/Call Ratio
Compares institutional put options with call options. At 0.00, the ratio is below 1, so institutions hold more calls than puts.
| Put/Call Ratio | 0.0000▼ 110.31% |
|---|---|
| Total Calls | 600▼ 99.93% |
| Total Puts | -▼ 100.00% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 1.62%▼ 73.68% |
|---|---|
| Total Invested | $153.18M▼ 98.37% |
| Investors Holding | 112▼ 428.00% |
About Axsome Therapeutics Inc
712 employees
CEO: Herriot Tabuteau
Axsome Therapeutics, Inc. is a biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders for which there are limited treatment options. For the many people facing unsatisfactory tre...